Skip to main content
    • Aa
    • Aa

Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: A systematic review and economic evaluation

  • Jonathan Shepherd (a1), Håkan F. T. Brodin (a1), Carolyn Backer Cave (a1), Norman R. Waugh (a2), Alison Price (a1) and John Gabbay (a1)...

Objectives: To assess the clinical-effectiveness and cost-effectiveness of pegylated interferon alfa (2a and 2b) combined with ribavirin in previously untreated patients with moderate to severe chronic hepatitis C, compared with the current standard treatment, which is nonpegylated interferon alfa combined with ribavirin.

Methods: Systematic review and economic evaluation. A sensitive search strategy was applied to several electronic bibliographic databases. Relevant studies were critically appraised and meta-analyzed. A hypothetical cohort of 1,000 patients entered a Markov model and were followed up for a more than 30-year period to predict natural history, duration spent in each health state, and treatment costs.

Results: Two fully published Phase III randomized controlled trials were included. Methodological quality was generally good. Dual therapy with pegylated interferon was significantly more effective than nonpegylated dual therapy with a pooled sustained virological response rate (SVR) of 55 percent (95 percent confidence interval [CI], 52–58 percent) compared with 46 percent (95 percent CI, 43–49 percent). The pooled relative risk of remaining infected was 0.83 (95 percent CI, 0.76–0.91 percent). Genotype was the strongest predictor of outcome, with SVRs in patients with the more responsive genotypes 2 and 3 reaching up to 80 percent. The incremental cost per quality-adjusted life year (QALY) for pegylated dual therapy compared with nonpegylated dual therapy was £12,123. The cost per QALY remained under £30,000 for most patient subgroups and in sensitivity analyses.

Conclusions: Pegylated interferon is clinically effective, represents good value for the money, and is a significant advance in the treatment of this insidious disease.

Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

BennettWG, InoueY, BeckJR, et al. 1997 Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 127: 855865.

ButiM, MedinaM, CasadoMA, et al. 2003 A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther. 17: 687694.

DavisGL. 2001 Treatment of chronic hepatitis C. BMJ. 323: 11411142.

DavisGL. 2002 Monitoring of viral levels during therapy of hepatitis C. Hepatology. 36: S145S151.

DavisGL, EstebanMR, RustgiV, et al. 1998 Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 339: 14931499.

Di BisceglieAM. 1998 Hepatitis C. Lancet. 351: 351355.

FortonDM, ThomasHC, MurphyCA, et al. 2002 Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 35: 433439.

FriedMW, ShiffmanML, ReddyKR, et al. 2002 Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 347: 975982.

HadziyannisSJ, SetteH, MorganTR, et al. 2004 Peginterferon-á 2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med. 140: 346355.

KimWR, PoteruchaJJ, HermansJE, et al. 1997 Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med. 127: 866874.

MannsMP, McHutchisonJG, GordonSC, et al. 2001 Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 358: 958965.

PoynardT, BedossaP, OpolonP. 1997 Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349: 825832.

PoynardT, McHutchisonJ, GoodmanZ, et al. 2000 Is an “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology. 31: 211218.

ShepherdJ, BrodinH, CaveC, et al. 2004; Pegylated interferon alpha 2a and 2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Health Technol Assess. 8.

SiebertU, SroczynskiG, RossolS, et al. 2003 Cost-effectiveness of peginterferon 2 b plus ribavirin versus interferon 2b plus ribavirin for initial treatment of chronic hepatitis C. Gut. 52: 425432.

VerbaanHP, WidellHE, BondesonTL, LindgrenSC. 2002 High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin. Eur J Gastroenterol Hepatol. 14: 627633.

WongJB, BennettWG, KoffRS, PaukerSG. 1998 Pretreatment evaluation of chronic hepatitis C: Risks, benefits, and costs. JAMA. 280: 20882093.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *



Altmetric attention score

Full text views

Total number of HTML views: 1
Total number of PDF views: 15 *
Loading metrics...

Abstract views

Total abstract views: 113 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 22nd September 2017. This data will be updated every 24 hours.